

Precision Medicine: RET-Targeted Thyroid Carcinoma

Resource	Address
James A. Fagin, and Samuel A. Wells, Jr. Biologic and Clinical Perspectives on Thyroid Cancer. <i>N Engl J Med</i> . 2016;375:1054-67.	https://pubmed.ncbi.nlm.nih.gov/27626519/
Geoffrey W. Krampitz, Jeffrey A. Norton. RET Gene Mutations (Genotype and Phenotype) of Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma. <i>Cancer</i> . 2014;120: 1920-1931.	https://pubmed.ncbi.nlm.nih.gov/24699901/
Mulligan L. RET revisited: expanding the oncogenic portfolio. <i>Nat Rev Cancer</i> . 2014 Mar;14(3):173-186.	https://pubmed.ncbi.nlm.nih.gov/24561444/
Ciampi R, Romei C. Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. <i>iScience</i> . 2019 Oct 25;20:324-336.	https://pubmed.ncbi.nlm.nih.gov/31605946/
Pierre Vanden Borre, Alexa B Schrock. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. <i>Oncologist</i> . 2017 Mar;22(3):255-263.	https://pubmed.ncbi.nlm.nih.gov/28209747/
American Thyroid Association.	https://www.thyroid.org/cancer-of-the-thyroid/

Treatment of RET-driven Thyroid Carcinomas

Resource	Address
Wirth L, Sherman E. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. <i>NEJM</i> . 2020;383:825-835.	https://pubmed.ncbi.nlm.nih.gov/32846061/
Ole Vincent Ancker, Marcus Krüger. Multikinase Inhibitor Treatment in Thyroid Cancer. <i>Int J Molecular Sci</i> . 2019;21:10.	https://pubmed.ncbi.nlm.nih.gov/31861373/
Vivek Subbiah; Dong Yang. State-of-the-Art Strategies for Targeting RET-Dependent Cancers. <i>JCO</i> . 2020;38:1209-1221.	https://pubmed.ncbi.nlm.nih.gov/32083997/
Roy S Herbst, John V Heymach. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. <i>Exp Opin Invest Drugs</i> . 2007;16:239-249.	https://pubmed.ncbi.nlm.nih.gov/17243944/
David Viola, MD, Rossella Elisei. Management of Medullary Thyroid Cancer. <i>Endocrinol Metab Clin N Am</i> . 2019;48:285-301.	https://pubmed.ncbi.nlm.nih.gov/30717909/

Dora Dias-Santagata, Jochen K. Lennerz. Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. <i>Thyroid</i> . 2020;00. DOI: 10.1089/thy.2019.0477	https://pubmed.ncbi.nlm.nih.gov/32292131/
Vera Tiedje; James A. Fagin . Therapeutic breakthroughs for metastatic thyroid cancer. <i>Nat Rev Endocrinol</i> . 2020;16:77-78.	https://pubmed.ncbi.nlm.nih.gov/31819229/
S. Filetti, C. Durante. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i> . 2019;30:1856-1883.	https://pubmed.ncbi.nlm.nih.gov/31549998/
Subbiah V, Gainor J. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. <i>Cancer Discov</i> . 2018;8(7);836-849.	https://pubmed.ncbi.nlm.nih.gov/29657135/
Rossella Elisei, Martin J. Schlumberger. Cabozantinib in Progressive Medullary Thyroid Cancer. <i>JCO</i> . 2013;31(29):3639-3646.	https://pubmed.ncbi.nlm.nih.gov/24002501/
M. Schlumberger, R. Elisei. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. <i>Ann Oncol</i> . 2017;28: 2813-2819.	https://pubmed.ncbi.nlm.nih.gov/29045520/
ThyCa: Thyroid Cancer Survivors' Association, Inc.	http://www.thyca.org/about/ata/